About ERO1-like protein beta
ERO1-like protein beta (ERO1B) is a protein
from Homo sapiens identified by UniProt accession
Q86YB8, 467 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | ERO1-like protein beta |
| UniProt accession | Q86YB8 |
| Gene | ERO1B |
| Organism | Homo sapiens |
| Length | 467 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (74)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.29
- bone benign neoplasm · score 0.26
- endometrial cancer · score 0.18
- cortical surface area measurement · score 0.13
- early-onset non-syndromic cataract · score 0.12
- Developmental cataract · score 0.12
- brain measurement · score 0.10
- MODY · score 0.10
- type 2 diabetes mellitus · score 0.09
- type 1 diabetes mellitus · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86YB8-F1 | alphafold | PREDICTED | 75.62 | — |
Amino-acid sequence (467 residues)
MSQGVRRAGA GQGVAAAVQL LVTLSFLRSV VEAQVTGVLD DCLCDIDSID NFNTYKIFPK IKKLQERDYF RYYKVNLKRP CPFWAEDGHC SIKDCHVEPC PESKIPVGIK AGHSNKYLKM ANNTKELEDC EQANKLGAIN STLSNQSKEA FIDWARYDDS RDHFCELDDE RSPAAQYVDL LLNPERYTGY KGTSAWRVWN SIYEENCFKP RSVYRPLNPL APSRGEDDGE SFYTWLEGLC LEKRVFYKLI SGLHASINLH LCANYLLEET WGKPSWGPNI KEFKHRFDPV ETKGEGPRRL KNLYFLYLIE LRALSKVAPY FERSIVDLYT GNAEEDADTK TLLLNIFQDT KSFPMHFDEK SMFAGDKKGA KSLKEEFRLH FKNISRIMDC VGCDKCRLWG KLQTQGLGTA LKILFSEKEI QKLPENSPSK GFQLTRQEIV ALLNAFGRLS TSIRDLQNFK VLLQHSR
Explore ERO1-like protein beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets